C4 Therapeutics, Inc.

CCCC

US12529R1077

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-10 pm EST			5-day change	1st Jan Change
4.310 ^USD	+2.86%		+0.23%	-23.72%

Dec. 08	C4 Therapeutics, Inc. - Special Call
Nov. 20	C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors	CI

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about C4 Therapeutics, Inc.

C4 Therapeutics, Inc. - Special Call	Dec. 08
C4 Therapeutics, Inc. Appoints Steve Hoerter as Board of Directors	Nov. 20	CI
C4 Therapeutics, Inc. Announces First Patient Dosed in CFT8919 Clinical Trial	Nov. 06	CI
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma At the American Society of Hematology Annual Meeting	Nov. 05	CI
C4 Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Oct. 31	CI
C4 Therapeutics Names Paige Mahaney as Chief Scientific Officer	Oct. 15	MT
C4 Therapeutics, Inc. Announces Executive Changes	Oct. 15	CI
Evercore ISI Lifts Price Target on C4 Therapeutics to $10 From $9, Keeps Outperform Rating	Sep. 16	MT
C4 Therapeutics, Inc. - Special Call	Sep. 13
C4 Therapeutics Says Protein Degrader Candidate 'Well-Tolerated' in Early Phase 1 Data	Sep. 13	MT
C4 Therapeutics, Inc. Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept from Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at European Society for Medical Oncology Congress 2024	Sep. 13	CI
C4 Therapeutics Delivers Final Development Candidate Under Biogen Deal	Sep. 10	MT
Top Premarket Decliners	Sep. 09	MT
C4 Therapeutics, Inc. Announces Board Changes	Sep. 03	CI
C4 Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 01	CI
Engene Holdings Inc. Announces Appointment of Ron Cooper as Chief Executive Officer	Jul. 24	CI
C4 Therapeutics, Inc. Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 12:00 PM	Jul. 15
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell Small Cap Comp Value Index	Jun. 30	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell Small Cap Completeness Index	Jun. 30	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 3000 Value Index	Jun. 30	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 2000 Index	Jun. 30	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 3000E Index	Jun. 30	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 2500 Value Index	Jun. 30	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 2000 Value Index	Jun. 30	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 2000 Dynamic Index	Jun. 30	CI

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patientsâ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the bodyâs natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.

Employees

145

Sector

Biotechnology & Medical Research

Calendar

2025-02-19 - Q4 2024 Earnings Release (Projected)

More about the company